Vinorelbine Sandoz 10 mg/ml (Injection)

10 mg vial: ৳ 1,600.00

Medicine Details

Category Details
Generic Vinorelbine tartrate
Company Sandoz a novartis division

Indications

  • First-line treatment for locally advanced or metastatic non-small cell lung cancer in combination with cisplatin
  • Single agent treatment for metastatic non-small cell lung cancer

Pharmacology

  • Vinorelbine binds to tubulin
  • Inhibits microtubule formation
  • Arrests the cell at metaphase

Dosage & Administration

  • Intravenous administration for cervical, breast, and ovarian cancer
  • Different dosages for different types of cancer
  • Oral administration for non-small cell lung cancer

Interaction

  • Increased risk of granulocytopenia with cisplatin
  • Increased neurotoxicity risk with paclitaxel, itraconazole, and ketoconazole
  • Increased radiosensitising effects with radiation therapy
  • Increased pulmonary toxicity with mitomycin
  • Increased myelotoxicity with zidovudine
  • Possible increase in vincristine levels with aprepitant
  • Possible infection with live vaccines

Contraindications

  • Hypersensitivity to vinorelbine or other vinca alkaloids
  • Severe current or recent infection
  • Neutropenia
  • Thrombocytopenia
  • Severe hepatic impairment
  • Intrathecal administration
  • Concomitant use with radiotherapy if liver is in the treatment field
  • Pregnancy
  • Lactation

Side Effects

  • Neurotoxicity
  • Peripheral paraesthesia
  • Loss of deep tendon reflexes
  • Abdominal pain
  • Severe constipation
  • Diarrhoea
  • Alopecia
  • Severe local irritation
  • Dose limiting granulocytopenia
  • Leukopenia
  • Anaemia
  • Intestinal obstruction
  • Paralytic ileus
  • Nausea
  • Vomiting
  • Increased liver function tests
  • Chest pain
  • Fatigue
  • Local pain and thrombophlebitis with injection

Pregnancy & Lactation

  • Pregnancy Category D
  • Positive evidence of human fetal risk
  • Benefits from use may be acceptable in life-threatening situations or serious diseases

Precautions & Warnings

  • Hepatic impairment
  • Compromised bone marrow reserve
  • Prior radiation therapy
  • Neuropathy
  • Monitoring CBC with differentials
  • Vein flushing after administration
  • Avoiding extravasation
  • Use of effective contraception during and after treatment
  • Oral administration precautions

Use in Special Populations

  • Dose adjustments for hepatic impairment in different types of cancer

Therapeutic Class

  • Cytotoxic Chemotherapy

Storage Conditions

  • Intravenous: Store at 2-8°C, protect from light
  • Oral: Store at 2-8°C

Related Brands